Show results for
Refine by
Clinic Celiacshield Trial Suppliers In Canada
13 companies found
based inRichmond, BRITISH COLUMBIA (CANADA)
BioMark is an oncology-focused company with advanced near-to- market liquid biopsy diagnostic technologies. Our technology improves patient comfort, outcomes and early cancer detection. Biomark owns various intellectual properties, developed for the ...
BioMark’s initial liquid biopsy assay detects SSAT1 using an FDA approved drug. SSAT1 is an enzyme with elevated levels in numerous cancers. The assay targets a well researched and understood metabolic pathway. BioMark of a few unique ...
based inWest Vancouver, BRITISH COLUMBIA (CANADA)
Focusing initially on breast cancer, BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) is dedicated to enhancing the lives of people with cancer with limited therapy options by developing novel immunotherapies to fight cancer. ...
Phase I/IIa Combination Study of Bria-IMT™ with retifanlimab (INCMGA00012) and epacadostat in Advanced Breast Cancer. FDA has approved the combination study of Bria-IMT™ with Incyte Corporation’s drugs, retifanlimab and ...
based inToronto, ONTARIO (CANADA)
Spectral’s vision is to provide a personalized approach that will enable vastly improve outcomes for patients with septic shock by combining a targeted diagnostic test and therapy. It is widely known that endotoxin is a trigger of sepsis. Spectral ...
PMX is a Polymyxin B extracorporeal direct hemoperfusion adsorption column which is highly effective in removing endotoxin in the bloodstream. Clinically available since 1995*. As of 2019, more than 200,000 treatments performed . Reproducible ...
based inVictoria, BRITISH COLUMBIA (CANADA)
IPA (ImmunoPrecise Antibodies NASDAQ: IPA ) is a biotherapeutic research company that brings industry leading antibody discovery services and complex artificial intelligence technologies together - to lead its pharmaceutical partners into the era of ...
based inMississauga, ONTARIO (CANADA)
Award-winning, Clinical Stage/Life-Sciences company focused on the drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors. The company is targeting anxiety, depression, ...
Mentanine®, supported by (cannabidiol “CBD” + IP formula) – molecules bond and synergistically attach to PPAR receptors allowing the formula to cross the blood-brain barrier (BBB) to target the central nervous ...
based inToronto, ONTARIO (CANADA)
Shiphrah Biomedical Inc. is a Toronto-based, Canadian, biomedical technology start-up specializing in evidence-based design of medical devices to advance and improve women’s health. Established by a clinician-engineer-scientist in March 2019, ...
Research is a massive undertaking that many companies are unwilling to engage in for a variety of factors. This is especially true when it comes to women’s health research, and within women’s health, there is a long history of excluding ...
based inVancouver, BRITISH COLUMBIA (CANADA)
InMed Pharmaceuticals is a global leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet ...
INM-088 is a topical eye drop formulation under development for the treatment of glaucoma. The active pharmaceutical ingredient (API) in INM-088 is cannabinol, also known as CBN, a rare cannabinoid showing promise in its potential to provide ...
based inToronto, ONTARIO (CANADA)
Avicanna is a Canadian biopharmaceutical company providing the global marketplace with advanced natural cannabinoid solutions through an evidence-based approach offered across several product platforms including API, medical, pharmaceutical, and ...
based inThorold, ONTARIO (CANADA)
Norgen Biotek Corp. is dedicated to providing our customers with first class sample preparation kits for RNA, microRNA, DNA and protein purification, clean-up and concentration and to provide dedicated and expert support services to our customers ...
Norgen Biotek is accredited to ISO 15189:2012, emphasizing our commitment to quality in our laboratory and R&D services. Norgen offers a number of laboratory services to the scientific community and for medical device developers and ...
based inDieppe, NEW BRUNSWICK (CANADA)
Triple Hair aims to be a global leader in clinical research for Androgenetic Alopecia and is making great strides in developing solutions for thinning hair and hair loss with successful dense regrowth. After testing all known hair loss treatments ...
This innovative triple combination therapy promotes hair regrowth in men with androgenic alopecia. Its exclusive combination of molecules acts at various stages of the hair growth cycle to stop hair loss and stimulate regrowth, while also making ...
based inCalgary, ALBERTA (CANADA)
Hemostemix (TSX V:HEM; OTCQB:HMTXF) is a clinical-stage biotechnology company focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. Hemostemix’s proprietary platform technology is based on more ...
Hemostemix’s technology uses a patient’s own cells to treat that patient’s disease. The cornerstone of this autologous technology is a novel cell population within the blood called the synergetic cell population (SCP). The ...
based inToronto, ONTARIO (CANADA)
Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in people with diabetes. This pre-clinical technology is directed at regulating a hormone in the pancreas called somatostatin which in Type ...
based inVancouver, BRITISH COLUMBIA (CANADA)
Zymeworks Inc. is a publicly listed (NYSE: ZYME), clinical-stage, biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of ...
Zymeworks’ lead product candidate, zanidatamab, is a HER2-targeted bispecific antibody developed using Zymeworks proprietary Azymetric platform. Zanidatamab is currently being evaluated in global Phase 1, Phase 2 and pivotal clinical trials as ...